The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Improved Biomarkers and Clinical Outcome Measures, 2019Correlating MRI, Pathology and Cognitive Assessments toward Biomarkers of Cognitive Decline
Study Rationale:
Parkinson’s studies are working to identify magnetic resonance imaging (MRI) biomarkers for early diagnosis, disease severity and progression. However, attempts to explore how brain... -
Research Grant, 2019Longitudinal Examination of Problems that Bother People with Parkinson’s
Study Rationale:
Using the Fox Insight research platform, we extracted and analyzed reports in patients’ own words about what problems bother them and how these problems affect their daily functioning... -
Therapeutic Pipeline Program, 2019Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic
Study Rationale:
There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune... -
Research Grant, 2019The Synaptic Vesicle Cycle in Parkinson’s Disease
Study Rationale:
Many of the proteins implicated in Parkinson’s disease appear to have a role at the nerve terminal, presumably in neurotransmitter release. However, the function of most has remained... -
GBA Biology and Therapies, 2019Expression of GCase throughout Brain Vasculature for Degradation of Alpha-synuclein Aggregates
Study Rationale:
Alpha-synuclein toxicity is caused by progressive accumulation of this protein in cells. Alpha-synuclein protein aggregation is helped along by impaired lysosomes... -
Research Grant, 2019Validation of Microglial CRAC Channels as a Therapeutic Target for Parkinson’s Disease
Study Rationale:
Inflammation of the central nervous system mediated by microglial cells is a major feature of Parkinson’s disease. Vivreon Biosciences is developing Parkinson’s disease therapeutics...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.